Evidence map›Paper›PMID 41625910›Full record

ArticleCureus2025

Identifying Potential Drug Targets for Membranous Nephropathy Through an Analysis of Mendelian Randomization.

Yasin Abdi Saed, Ahmed Ibrahim Mohamed, Mohamed Mohamoud Adan, Muhammad Attique, Noor Sarfraz

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yasin Abdi SaedDepartment of Medicine, International College of Medicine and Pharmacy, Changsha Medical University, Changsha, CHN.
Ahmed Ibrahim MohamedHealth Science Center, Xi'an Jiaotong University, Xi'an, CHN.
Mohamed Mohamoud AdanDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CHN.
Muhammad AttiqueDepartment of Medicine, International College of Medicine and Pharmacy, Changsha Medical University, Changsha, CHN.
Noor SarfrazDepartment of Medicine, International College of Medicine and Pharmacy, Changsha Medical University, Changsha, CHN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Membranous nephropathy (MN) is the most common cause of adult nephrotic syndrome. Current treatments rely heavily on immunosuppressants; however, some patients do not achieve the desired therapeutic effect. Therefore, the identification of new drug targets and the development of novel medications are of urgent importance. In this study, we collected protein quantitative trait loci (pQTLs) for 734 circulating plasma proteins (CPPs) from previous research. Using principles of Mendelian genetics, we conducted a Mendelian randomization (MR) analysis using three inferential methods: the Wald ratio, inverse-variance weighted (IVW), and MR-Egger. After assessing heterogeneity, we identified 16 CPPs that were positively correlated with the occurrence of MN and 14 CPPs that were negatively correlated with MN. Enrichment analysis showed that these CPPs are primarily involved in oxidative stress and inflammation pathways, which are closely related to the development and progression of MN. Subsequently, using the Drug Signatures Database (DsigDB), we predicted potential drugs that might interact with these CPPs. Finally, we found that curcumin, a natural compound known for its antioxidant, anti-inflammatory, and immunomodulatory properties, could be a potential therapeutic molecule for the treatment of MN. This study aimed to systematically screen CPPs for causal associations with MN risk using MR, characterize the biological pathways of implicated proteins, and nominate potential therapeutic agents via computational drug repurposing analysis.

Indexed as

circulating plasma proteindrug repositioningmembranous nephropathymendelian randomizationretrospective

Identifiers

PMID41625910
PMCPMC12854156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.